{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:52:16Z","timestamp":1792093936573,"version":"4.4.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000875","name":"The Pew Charitable Trusts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000875","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013140","name":"Colorectal Cancer Alliance Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013140","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Host & Microbe"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.chom.2026.08.008","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:41:12Z","timestamp":1791988872000},"page":"1862-1864","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["From blunt to precision: Engineering microbiome therapeutics against cancer"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2960-8047","authenticated-orcid":false,"given":"Abigail E.","family":"Rose","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3771-0842","authenticated-orcid":false,"given":"Wenhan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chom.2026.08.008_bib1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.cell.2018.08.041","article-title":"Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features","volume":"174","author":"Zmora","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.chom.2026.08.008_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-73465-7","article-title":"Integration of donor microbiota following FMT correlates with anti-PD-1 response in melanoma","volume":"17","author":"Fessler","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.chom.2026.08.008_bib3","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/s41564-025-01930-y","article-title":"Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses","volume":"10","author":"Sardar","year":"2025","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.chom.2026.08.008_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature08529","article-title":"Uptake through glycoprotein 2 of FimH+ bacteria by M cells initiates mucosal immune response","volume":"462","author":"Hase","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.chom.2026.08.008_bib5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/s41551-022-00886-2","article-title":"Antigen-bearing outer membrane vesicles as tumour vaccines produced in situ by ingested genetically engineered bacteria","volume":"6","author":"Yue","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.chom.2026.08.008_bib6","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/j.chom.2026.06.021","article-title":"Engineering oral commensal nanovaccines to activate mucosal-systemic immune cascades against tumor","volume":"34","author":"Zirong Dong","year":"2026","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2026.08.008_bib7","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.chom.2026.09.011","article-title":"An enzyme-responsive nanoplatform rewires host-microbe tryptophan metabolism for cancer immunotherapy","volume":"34","author":"Chao Pan","year":"2026","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.chom.2026.08.008_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): a phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.chom.2026.08.008_bib9","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.cell.2023.03.011","article-title":"Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment","volume":"186","author":"Bender","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.chom.2026.08.008_bib10","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2412070121","article-title":"Engineering bacteria for cancer immunotherapy by inhibiting IDO activity and reprogramming CD8+ T cell response","volume":"121","author":"Wang","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Cell Host & Microbe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826003513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1931312826003513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:42:54Z","timestamp":1792093374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1931312826003513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1931312826003513"],"URL":"https:\/\/doi.org\/10.1016\/j.chom.2026.08.008","relation":{},"ISSN":["1931-3128"],"issn-type":[{"value":"1931-3128","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From blunt to precision: Engineering microbiome therapeutics against cancer","name":"articletitle","label":"Article Title"},{"value":"Cell Host & Microbe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chom.2026.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}